296 related articles for article (PubMed ID: 22440906)
1. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi M; Tan SH; Voss D;
J Am Soc Nephrol; 2012 Jun; 23(6):1097-107. PubMed ID: 22440906
[TBL] [Abstract][Full Text] [Related]
2. The Trio Trial - A Randomized Controlled Clinical Trial Evaluating the Effect of a Biocompatible Peritoneal Dialysis Solution on Residual Renal Function.
Sikaneta T; Wu G; Abdolell M; Ng A; Mahdavi S; Svendrovski A; Tu T; Mercer T; Tong M; Oreopoulos D; Tam P
Perit Dial Int; 2016 9-10; 36(5):526-32. PubMed ID: 27282852
[TBL] [Abstract][Full Text] [Related]
3. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Perit Dial Int; 2012; 32(5):497-506. PubMed ID: 22991015
[TBL] [Abstract][Full Text] [Related]
4. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial.
Lui SL; Yung S; Yim A; Wong KM; Tong KL; Wong KS; Li CS; Au TC; Lo WK; Ho YW; Ng F; Tang C; Chan TM
Am J Kidney Dis; 2012 Dec; 60(6):966-75. PubMed ID: 22835900
[TBL] [Abstract][Full Text] [Related]
5. "Biocompatible" Neutral pH Low-GDP Peritoneal Dialysis Solutions: Much Ado About Nothing?
Misra PS; Nessim SJ; Perl J
Semin Dial; 2017 Mar; 30(2):164-173. PubMed ID: 28251697
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of neutral-pH, low-glucose degradation product peritoneal dialysis solutions compared with standard solutions: a secondary analysis of the balANZ Trial.
Howard K; Hayes A; Cho Y; Cass A; Clarke M; Johnson DW
Am J Kidney Dis; 2015 May; 65(5):773-9. PubMed ID: 25746151
[TBL] [Abstract][Full Text] [Related]
7. Three Versus 4 Daily Exchanges and Residual Kidney Function Decline in Incident CAPD Patients: A Randomized Controlled Trial.
Yan H; Fang W; Lin A; Cao L; Ni Z; Qian J
Am J Kidney Dis; 2017 Apr; 69(4):506-513. PubMed ID: 27751610
[TBL] [Abstract][Full Text] [Related]
8. Effects of neutral pH and low-glucose degradation product-containing peritoneal dialysis fluid on systemic markers of inflammation and endothelial dysfunction: a randomized controlled 1-year follow-up study.
Park SH; Do JY; Kim YH; Lee HY; Kim BS; Shin SK; Kim HC; Chang YK; Yang JO; Chung HC; Kim CD; Lee WK; Kim JY; Kim YL
Nephrol Dial Transplant; 2012 Mar; 27(3):1191-9. PubMed ID: 21862454
[TBL] [Abstract][Full Text] [Related]
9. Could solutions low in glucose degradation products preserve residual renal function in incident peritoneal dialysis patients? A 1-year multicenter prospective randomized controlled trial (Balnet Study).
Kim SG; Kim S; Hwang YH; Kim K; Oh JE; Chung W; Oh KH; Kim HJ; Ahn C;
Perit Dial Int; 2008 Jun; 28 Suppl 3():S117-22. PubMed ID: 18552239
[TBL] [Abstract][Full Text] [Related]
10. Biocompatible dialysis fluids for peritoneal dialysis.
Cho Y; Johnson DW; Craig JC; Strippoli GF; Badve SV; Wiggins KJ
Cochrane Database Syst Rev; 2014 Mar; (3):CD007554. PubMed ID: 24671928
[TBL] [Abstract][Full Text] [Related]
11. Effect of biocompatible peritoneal dialysis solution on residual renal function: a systematic review of randomized controlled trials.
Seo EY; An SH; Cho JH; Suh HS; Park SH; Gwak H; Kim YL; Ha H
Perit Dial Int; 2014; 34(7):724-31. PubMed ID: 25185015
[TBL] [Abstract][Full Text] [Related]
12. Benefits of biocompatible PD fluid for preservation of residual renal function in incident CAPD patients: a 1-year study.
Kim S; Oh J; Kim S; Chung W; Ahn C; Kim SG; Oh KH
Nephrol Dial Transplant; 2009 Sep; 24(9):2899-908. PubMed ID: 19258384
[TBL] [Abstract][Full Text] [Related]
13. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique survival.
Srivastava S; Hildebrand S; Fan SL
Kidney Int; 2011 Nov; 80(9):986-991. PubMed ID: 21814174
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the balANZ trial: a randomised controlled trial of low GDP, neutral pH versus standard peritoneal dialysis solution for the preservation of residual renal function.
Johnson DW; Clarke M; Wilson V; Woods F; Brown FG
BMC Nephrol; 2010 Sep; 11():25. PubMed ID: 20843375
[TBL] [Abstract][Full Text] [Related]
16. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance).
Lee HY; Park HC; Seo BJ; Do JY; Yun SR; Song HY; Kim YH; Kim YL; Kim DJ; Kim YS; Ahn C; Kim MJ; Shin SK
Perit Dial Int; 2005; 25(3):248-55. PubMed ID: 15981773
[TBL] [Abstract][Full Text] [Related]
17. Predictors of Residual Renal Function Decline in Peritoneal Dialysis Patients: The
Htay H; Cho Y; Pascoe EM; Darssan D; Hawley C; Johnson DW;
Perit Dial Int; 2017; 37(3):283-289. PubMed ID: 27935537
[TBL] [Abstract][Full Text] [Related]
18. The effect of low glucose degradation product, neutral pH versus standard peritoneal dialysis solutions on peritoneal membrane function: the balANZ trial.
Johnson DW; Brown FG; Clarke M; Boudville N; Elias TJ; Foo MW; Jones B; Kulkarni H; Langham R; Ranganathan D; Schollum J; Suranyi MG; Tan SH; Voss D;
Nephrol Dial Transplant; 2012 Dec; 27(12):4445-53. PubMed ID: 22859794
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of a peritoneal dialysis program in remote communities within Colombia.
Sanabria M; Devia M; Hernández G; Astudillo K; Trillos C; Uribe M; Latorre C; Bernal A; Rivera A;
Perit Dial Int; 2015; 35(1):52-61. PubMed ID: 24497583
[TBL] [Abstract][Full Text] [Related]
20. Glucose Exposure in Peritoneal Dialysis Is a Significant Factor Predicting Peritonitis.
Uiterwijk H; Franssen CFM; Kuipers J; Westerhuis R; Nauta FL
Am J Nephrol; 2020; 51(3):237-243. PubMed ID: 32069459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
